Nicotinic Receptor Levels After Stopping Smoking

Status Completed

Clinical Trial Summary

This positron emission tomography (PET) study examines the effects of 24 hours abstinence from smoking on return to availability of neuronal nicotinic receptors in slow and fast metabolizers of nicotine.

Clinical Trial Description

The nicotine metabolite ratio (NMR), a stable marker of nicotine clearance rate, is a robust predictor of smoking relapse. Individuals who are fast nicotine metabolizers have higher rates of relapse, compared to slow metabolizers, on nicotine replacement or placebo treatment. Nicotine exerts its reinforcing properties, in part, by binding to α4β2* nicotinic acetylcholine receptors (nAChRs) in the brain. The α4β2* nAChRs are abundant and have high affinity for nicotine relative to other nAChR subtypes. The goal of this project is to identify abstinence-induced changes in neuronal nicotinic receptor availability that may underlie risk for smoking relapse.

The investigators propose to utilize positron emission tomography (PET) imaging to examine the association of variation in nicotine metabolism with return to availability of α4β2* nAChRs during early abstinence. The investigators will measure α4β2* receptor availability using the PET radio-ligand 2-[18F]FA, administered with bolus injection, on two separate occasions: during smoking as usual and after 24 hours of abstinence. The proposed study will help us understand the neurochemical mechanisms that underlie the higher risk of relapse among faster nicotine metabolizers, thereby pointing to potential targets for tailored therapy for these smokers at increased risk.

In addition, the investigators will invite six subjects who have completed the two PET scans described above to complete a third PET scan. During this third PET scan, the investigators plan to measure α4β2* receptor availability using the PET radio-ligand 2-[18F]FA, administered as bolus plus constant infusion after 24 hours of abstinence. The purpose will be to compare α4β2* nAChR binding potential data from the bolus 2-[18F]FA infusion protocol used in the main study to the bolus plus constant infusion protocol used in this third PET scan.

The protocol of this third PET scan will help the investigators demonstrate the feasibility at the University of Pennsylvania of administering the radiotracer as a bolus plus constant infusion, and the feasibility of scanning for two hours (versus one hour in the current protocol) paradigm. This data is important pilot data for future NIH grant submissions using this radiotracer. ;

Study Design

Related Conditions & MeSH terms

Nicotine Addiction

Clinical Trial Details

NCT number	NCT01704573
Study type	Observational
Source	University of Pennsylvania
Contact
Status	Completed
Phase	N/A
Start date	October 2010
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Completed	`NCT02153749` - Effects of Brief Training on Craving Regulation	N/A
Recruiting	`NCT05530577` - Effects of Semaglutide on Nicotine Intake	Phase 2
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT01944423` - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine	Early Phase 1
Active, not recruiting	`NCT01015170` - STOP Study: Effectiveness of Zyban in a Clinical Population	Phase 4
Completed	`NCT03281629` - Circuitry-Guided Smoking Cessation in Schizophrenia	N/A
Recruiting	`NCT06291584` - Effects of Exercises on Functional Capacity	N/A
Withdrawn	`NCT06259630` - Nicotine Virtual Reality Conditioned Place Preference	Phase 4
Completed	`NCT02624284` - tDCS Effects on Resisting Smoking: Dose Ranging Study	N/A
Active, not recruiting	`NCT02837510` - Neural Mechanisms Associated With Risk of Smoking Relapse	N/A
Completed	`NCT02656745` - Clinical Trial of Smoking Cessation Mobile Phone Program	N/A
Completed	`NCT01062932` - Investigation of Cycloserine as a Smoking Cessation Treatment	Phase 1
Completed	`NCT03069482` - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness	Phase 1
Completed	`NCT02870218` - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use	Phase 2
Terminated	`NCT01756053` - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward	Phase 2
Completed	`NCT01252966` - Cognitive Training for Nicotine Dependence	N/A
Active, not recruiting	`NCT04946825` - Quit Smoking Study for People Who Use E-Cigarettes	Phase 2
Recruiting	`NCT05434429` - Mobile Health for Problematic Behaviors and Substance Use	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.